Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × INDUSTRY × Malignant Disease × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1896 Breast Neoplasms 1413 Carcinoma, Non-Small-Cell Lung 1170 Prostatic Neoplasms 737 Colorectal Neoplasms 676 Neoplasm Metastasis 622 Multiple Myeloma 541 Melanoma 525 Ovarian Neoplasms 453 Lung Neoplasms 441 Lymphoma, Non-Hodgkin 384 Lymphoma 371 Recurrence 369 Leukemia, Myeloid, Acute 365 Pancreatic Neoplasms 354 Carcinoma, Renal Cell 336 Carcinoma, Hepatocellular 285 Stomach Neoplasms 276 Leukemia, Lymphocytic, Chronic, B-Cell 268 Lymphoma, Follicular 253 Head and Neck Neoplasms 244 Glioblastoma 219 Leukemia 215 Small Cell Lung Carcinoma 180 Lymphoma, Large B-Cell, Diffuse 180 Squamous Cell Carcinoma of Head and Neck 179 Urinary Bladder Neoplasms 175 Carcinoma 175 Uterine Cervical Neoplasms 174 Advanced Solid Tumors 160

Interventions

amuvatinib 1 Topotecan 1 Paclitaxel 1 Etoposide 1 Erlotinib Hydrochloride 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00881166 2024-08-02

SGI-0470-02

Astex Pharmaceuticals, Inc.

Phase 1 Completed

Malignant Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡